Nektar Therapeutics – Product Pipeline Review – 2013
Summary
Global Market Direct’s pharmaceuticals report, “Nektar Therapeutics - Product Pipeline Review - 2013” provides data on the Nektar Therapeutics’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Nektar Therapeutics’s corporate website, SEC filings, investor presentations and featured press releases, both from Nektar Therapeutics and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “Nektar Therapeutics - Product Pipeline Review - 2013” provides data on the Nektar Therapeutics’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Nektar Therapeutics’s corporate website, SEC filings, investor presentations and featured press releases, both from Nektar Therapeutics and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Nektar Therapeutics - Brief Nektar Therapeutics overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Nektar Therapeutics human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Nektar Therapeutics with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Nektar Therapeutics’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Nektar Therapeutics’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Nektar Therapeutics in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Nektar Therapeutics’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Nektar Therapeutics.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Nektar Therapeutics and identify potential opportunities in those areas.
Nektar Therapeutics Snapshot
Nektar Therapeutics Overview
Key Information
Key Facts
Nektar Therapeutics – Research and Development Overview
Key Therapeutic Areas
Nektar Therapeutics – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Nektar Therapeutics – Pipeline Products Glance
Nektar Therapeutics – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Nektar Therapeutics Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Nektar Therapeutics – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Nektar Therapeutics – Drug Profiles
Cytokine
Product Description
Mechanism of Action
R&D Progress
Drug For Nociceptive Pain
Product Description
Mechanism of Action
R&D Progress
Drug For Visceral Pain
Product Description
Mechanism of Action
R&D Progress
etirinotecan pegol
Product Description
Mechanism of Action
R&D Progress
etirinotecan pegol + [fluorouracil]
Product Description
Mechanism of Action
R&D Progress
Kinase Inhibitor
Product Description
Mechanism of Action
R&D Progress
Longer Acting Therapeutic Clotting Proteins
Product Description
Mechanism of Action
R&D Progress
NKTR-125
Product Description
Mechanism of Action
R&D Progress
NKTR-140
Product Description
Mechanism of Action
R&D Progress
NKTR-171
Product Description
Mechanism of Action
R&D Progress
NKTR-181
Product Description
Mechanism of Action
R&D Progress
NKTR-192
Product Description
Mechanism of Action
R&D Progress
NKTR-194
Product Description
Mechanism of Action
R&D Progress
NKTR-214
Product Description
Mechanism of Action
R&D Progress
NKTR-228
Product Description
Mechanism of Action
R&D Progress
Peptide Antibiotic
Product Description
Mechanism of Action
R&D Progress
Nektar Therapeutics – Pipeline Analysis
Nektar Therapeutics – Pipeline Products by Therapeutic Class
Nektar Therapeutics – Pipeline Products by Route of Administration
Nektar Therapeutics – Pipeline Products By Mechanism of Action
Nektar Therapeutics – Recent Pipeline Updates
Nektar Therapeutics - Dormant Projects
Nektar Therapeutics - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
NKTR-105
Nektar Therapeutics – Company Statement
Nektar Therapeutics – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Nektar Therapeutics, Recent Developments
Nektar Therapeutics- Press Release
Apr 07, 2013: Nektar Therapeutics Presents Positive Preclinical Data For NKTR-214 at AACR Annual Meeting 2013
Feb 05, 2013: Nektar Announces Initiation Of Phase II Investigator-initiated Study Of Etirinotecan Pegol In Patients With Metastatic And Recurrent Non-Small Cell Lung Cancer
Dec 12, 2010: Nektar Reports Positive Phase II Study Results Of NKTR-102 In Metastatic Breast Cancer
Dec 09, 2010: Nektar To Present Phase II Clinical Data On NKTR-102 At Annual CTRC-AACR San Antonio Breast Cancer Symposium
Oct 15, 2010: Nektar Presents NKTR-181 Preclinical Data At Pain 2010 Conference
Jul 06, 2010: Nektar Presents Data On NKTR-102 In Nonclinical Studies In Tumor Models Of Gastrointestinal Cancers At ESMO
Jul 06, 2010: Nektar's NKTR-102 Demonstrates Superior Activity To Irinotecan In Nonclinical Studies In Tumor Models Of Gastrointestinal Cancer
Jun 24, 2010: Nektar Doses First Patients In Phase I Study Of NKTR-102 In Combination With 5-Fluorouracil/Leucovorin
Jun 09, 2010: Nektar Announces Positive Phase II Study Results Of NKTR-102 In Metastatic Breast Cancer
Jun 06, 2010: Nektar Announces NKTR-102 Positive Phase II Results In Platinum-Resistant/Refractory Ovarian Cancer
May 20, 2010: Nektar's NKTR-102 Phase II Clinical Data Accepted For Oral Presentation At 2010 ASCO Annual Meeting
Mar 09, 2010: Nektar Reports Positive Phase II Clinical Data From First Stage Of NKTR-102 Study In Women With Platinum-Resistant Ovarian Cancer
Jan 12, 2010: Nektar Therapeutics Announces first Stage Phase 2 Study Results Of NKTR-102 In Platinum-Resistant Ovarian Cancer
Financial Deals Landscape
Nektar Therapeutics, Deals Summary
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Pearl Therapeutics Secures Additional $18 Million In Series A Financing
Private Equity
Aerogen Completes Management Buyout
Partnerships
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Nektar Therapeutics Enters Into Co-Development Agreement With Bayer HealthCare
Licensing Agreements
Nektar Therapeutics Enters Into Licensing Agreement With AstraZeneca
Equity Offering
Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For $225 Million
Debt Offering
Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For $125 Million
Asset Transactions
Nektar Therapeutics To Sell Royalty Of CIMZIA and MIRCERA To RPI Finance Trust For $124 Million
Novartis Acquires Pulmonary Drug-Delivery Business Unit Of Nektar Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Nektar Therapeutics, Key Information
Nektar Therapeutics, Key Facts
Nektar Therapeutics – Pipeline by Indication, 2013
Nektar Therapeutics – Pipeline by Stage of Development, 2013
Nektar Therapeutics – Monotherapy Products in Pipeline, 2013
Nektar Therapeutics – Combination Treatment Modalities in Pipeline, 2013
Nektar Therapeutics – Phase III, 2013
Nektar Therapeutics – Phase II, 2013
Nektar Therapeutics – Phase I, 2013
Nektar Therapeutics – Pre-Clinical, 2013
Nektar Therapeutics – Discovery, 2013
Nektar Therapeutics – Pipeline By Therapeutic Class, 2013
Nektar Therapeutics – Pipeline By Route of Administration, 2013
Nektar Therapeutics – Pipeline Products By Mechanism of Action, 2013
Nektar Therapeutics – Recent Pipeline Updates, 2013
Nektar Therapeutics - Dormant Developmental Projects,2013
Nektar Therapeutics - Discontinued Pipeline Products, 2013
Nektar Therapeutics, Other Locations
Nektar Therapeutics, Subsidiaries
Nektar Therapeutics, Deals Summary
Pearl Therapeutics Secures Additional $18 Million In Series A Financing
Aerogen Completes Management Buyout
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Nektar Therapeutics Enters Into Co-Development Agreement With Bayer HealthCare
Nektar Therapeutics Enters Into Licensing Agreement With AstraZeneca
Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For $225 Million
Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For $125 Million
Nektar Therapeutics To Sell Royalty Of CIMZIA and MIRCERA To RPI Finance Trust For $124 Million
Novartis Acquires Pulmonary Drug-Delivery Business Unit Of Nektar Therapeutics
LIST OF FIGURES
Nektar Therapeutics – Pipeline by Indication, 2013
Nektar Therapeutics – Pipeline by Stage of Development, 2013
Nektar Therapeutics – Monotherapy Products in Pipeline, 2013
Nektar Therapeutics – Combination Treatment Modalities in Pipeline, 2013
Nektar Therapeutics – Pipeline By Therapeutic Class, 2013
Nektar Therapeutics – Pipeline By Route of Administration, 2013
Nektar Therapeutics - Pipeline Products By Mechanism of Action, 2013
Nektar Therapeutics Overview
Key Information
Key Facts
Nektar Therapeutics – Research and Development Overview
Key Therapeutic Areas
Nektar Therapeutics – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Nektar Therapeutics – Pipeline Products Glance
Nektar Therapeutics – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Nektar Therapeutics Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Nektar Therapeutics – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Nektar Therapeutics – Drug Profiles
Cytokine
Product Description
Mechanism of Action
R&D Progress
Drug For Nociceptive Pain
Product Description
Mechanism of Action
R&D Progress
Drug For Visceral Pain
Product Description
Mechanism of Action
R&D Progress
etirinotecan pegol
Product Description
Mechanism of Action
R&D Progress
etirinotecan pegol + [fluorouracil]
Product Description
Mechanism of Action
R&D Progress
Kinase Inhibitor
Product Description
Mechanism of Action
R&D Progress
Longer Acting Therapeutic Clotting Proteins
Product Description
Mechanism of Action
R&D Progress
NKTR-125
Product Description
Mechanism of Action
R&D Progress
NKTR-140
Product Description
Mechanism of Action
R&D Progress
NKTR-171
Product Description
Mechanism of Action
R&D Progress
NKTR-181
Product Description
Mechanism of Action
R&D Progress
NKTR-192
Product Description
Mechanism of Action
R&D Progress
NKTR-194
Product Description
Mechanism of Action
R&D Progress
NKTR-214
Product Description
Mechanism of Action
R&D Progress
NKTR-228
Product Description
Mechanism of Action
R&D Progress
Peptide Antibiotic
Product Description
Mechanism of Action
R&D Progress
Nektar Therapeutics – Pipeline Analysis
Nektar Therapeutics – Pipeline Products by Therapeutic Class
Nektar Therapeutics – Pipeline Products by Route of Administration
Nektar Therapeutics – Pipeline Products By Mechanism of Action
Nektar Therapeutics – Recent Pipeline Updates
Nektar Therapeutics - Dormant Projects
Nektar Therapeutics - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
NKTR-105
Nektar Therapeutics – Company Statement
Nektar Therapeutics – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Nektar Therapeutics, Recent Developments
Nektar Therapeutics- Press Release
Apr 07, 2013: Nektar Therapeutics Presents Positive Preclinical Data For NKTR-214 at AACR Annual Meeting 2013
Feb 05, 2013: Nektar Announces Initiation Of Phase II Investigator-initiated Study Of Etirinotecan Pegol In Patients With Metastatic And Recurrent Non-Small Cell Lung Cancer
Dec 12, 2010: Nektar Reports Positive Phase II Study Results Of NKTR-102 In Metastatic Breast Cancer
Dec 09, 2010: Nektar To Present Phase II Clinical Data On NKTR-102 At Annual CTRC-AACR San Antonio Breast Cancer Symposium
Oct 15, 2010: Nektar Presents NKTR-181 Preclinical Data At Pain 2010 Conference
Jul 06, 2010: Nektar Presents Data On NKTR-102 In Nonclinical Studies In Tumor Models Of Gastrointestinal Cancers At ESMO
Jul 06, 2010: Nektar's NKTR-102 Demonstrates Superior Activity To Irinotecan In Nonclinical Studies In Tumor Models Of Gastrointestinal Cancer
Jun 24, 2010: Nektar Doses First Patients In Phase I Study Of NKTR-102 In Combination With 5-Fluorouracil/Leucovorin
Jun 09, 2010: Nektar Announces Positive Phase II Study Results Of NKTR-102 In Metastatic Breast Cancer
Jun 06, 2010: Nektar Announces NKTR-102 Positive Phase II Results In Platinum-Resistant/Refractory Ovarian Cancer
May 20, 2010: Nektar's NKTR-102 Phase II Clinical Data Accepted For Oral Presentation At 2010 ASCO Annual Meeting
Mar 09, 2010: Nektar Reports Positive Phase II Clinical Data From First Stage Of NKTR-102 Study In Women With Platinum-Resistant Ovarian Cancer
Jan 12, 2010: Nektar Therapeutics Announces first Stage Phase 2 Study Results Of NKTR-102 In Platinum-Resistant Ovarian Cancer
Financial Deals Landscape
Nektar Therapeutics, Deals Summary
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Pearl Therapeutics Secures Additional $18 Million In Series A Financing
Private Equity
Aerogen Completes Management Buyout
Partnerships
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Nektar Therapeutics Enters Into Co-Development Agreement With Bayer HealthCare
Licensing Agreements
Nektar Therapeutics Enters Into Licensing Agreement With AstraZeneca
Equity Offering
Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For $225 Million
Debt Offering
Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For $125 Million
Asset Transactions
Nektar Therapeutics To Sell Royalty Of CIMZIA and MIRCERA To RPI Finance Trust For $124 Million
Novartis Acquires Pulmonary Drug-Delivery Business Unit Of Nektar Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Nektar Therapeutics, Key Information
Nektar Therapeutics, Key Facts
Nektar Therapeutics – Pipeline by Indication, 2013
Nektar Therapeutics – Pipeline by Stage of Development, 2013
Nektar Therapeutics – Monotherapy Products in Pipeline, 2013
Nektar Therapeutics – Combination Treatment Modalities in Pipeline, 2013
Nektar Therapeutics – Phase III, 2013
Nektar Therapeutics – Phase II, 2013
Nektar Therapeutics – Phase I, 2013
Nektar Therapeutics – Pre-Clinical, 2013
Nektar Therapeutics – Discovery, 2013
Nektar Therapeutics – Pipeline By Therapeutic Class, 2013
Nektar Therapeutics – Pipeline By Route of Administration, 2013
Nektar Therapeutics – Pipeline Products By Mechanism of Action, 2013
Nektar Therapeutics – Recent Pipeline Updates, 2013
Nektar Therapeutics - Dormant Developmental Projects,2013
Nektar Therapeutics - Discontinued Pipeline Products, 2013
Nektar Therapeutics, Other Locations
Nektar Therapeutics, Subsidiaries
Nektar Therapeutics, Deals Summary
Pearl Therapeutics Secures Additional $18 Million In Series A Financing
Aerogen Completes Management Buyout
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Nektar Therapeutics Enters Into Co-Development Agreement With Bayer HealthCare
Nektar Therapeutics Enters Into Licensing Agreement With AstraZeneca
Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For $225 Million
Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For $125 Million
Nektar Therapeutics To Sell Royalty Of CIMZIA and MIRCERA To RPI Finance Trust For $124 Million
Novartis Acquires Pulmonary Drug-Delivery Business Unit Of Nektar Therapeutics
LIST OF FIGURES
Nektar Therapeutics – Pipeline by Indication, 2013
Nektar Therapeutics – Pipeline by Stage of Development, 2013
Nektar Therapeutics – Monotherapy Products in Pipeline, 2013
Nektar Therapeutics – Combination Treatment Modalities in Pipeline, 2013
Nektar Therapeutics – Pipeline By Therapeutic Class, 2013
Nektar Therapeutics – Pipeline By Route of Administration, 2013
Nektar Therapeutics - Pipeline Products By Mechanism of Action, 2013
